Peter Bronsert

35PUBLICATIONS
172CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Clinical midwiferyPredictive and prognostic markersHaematological tumoursMedical infection agents (incl. prions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (35)

|Oct 23, 2026
Extracorporeal photopheresis for the treatment of steroid-refractory immune related adverse events from immune checkpoint inhibitor therapy: a multi-center phase Ib/II clinical trial.

|Sep 15, 2026
Expression of HER2 Ultralow in Endometrial Carcinoma, High-Grade Serous Ovarian Cancer and Their Metastases.

|Mar 24, 2026
Proteomic characterization of intrahepatic cholangiocarcinoma identifies risk-stratifying subgroups and EIF4A1 as a therapeutic target.

Tilman Werner, Johanna Thiery, Klara-Luisa Budau

|Feb 04, 2026
Activated ATF6α is a hepatic tumour driver restricting immunosurveillance.

Xin Li, Cynthia Lebeaupin, Aikaterini Kadianaki

|Apr 14, 2025
The Ectonucleotidases CD39 and CD73 and the Purinergic Receptor P2X4 Serve as Prognostic Markers in Non-Small Cell Lung Cancer.

Konrad Kurowski, Sophie Nicole Prozmann, António Eduardo Cabrita Figueiredo

|Feb 24, 2025
MCAM is a prognostic biomarker in patients with liver cirrhosis and HCC.

Eva Stockinger, Hendrik Luxenburger, Dominik Bettinger

Pageof 6

Frequent Collaborators

5 joint publications

Konrad Kurowski

4 joint publications

Ulrich Friedrich Wellner

3 joint publications

Tobias Keck

3 joint publications

Jens Hoeppner